Lannett Company Investor Relations

Lannett Company develops, manufactures, markets and distributes a broad spectrum of off-patent pharmaceutical products in a variety of dosage forms, including tablets, capsules, extended release, topicals, oral solutions and parenterals for sales in the generic drug market place. Additionally, the company has created a Specialty Pharma division for the marketing of its first brand drug, C-Topical, and, through its wholly owned subsidiary, develops and manufactures active pharmaceutical ingredients (APIs).

Based on the number of prescription transactions for unbranded generic products in the United States, Lannett is a top 25 company, according to IMS Health. Net sales were $151 million for fiscal 2013 and $193 million for the first nine months of fiscal 2014, representing a compounded annual growth rate of 24% since 2001. The company is committed to product development and has built a deep pipeline that includes a substantial number of product applications pending at the FDA in addition to a large number of product candidates in various stages of development.

The company intends to grow its business organically, as well as by acquiring complementary products or companies and forming strategic relationships. Lannett has targeted three areas of its business for expansion. The strategy for its base generics business is to commercialize products in its pipeline, develop products with market barriers to entry, acquire complementary products and form strategic relationships for developing products that enhance internal efforts. For its controlled substance business, the company intends to continue to invest in the development of higher margin products, with a focus on novel forms of delivery, to become a dominant player in the U.S. Lastly, the company will continue to ramp up its branded products business.

Each of Lannett’s business areas are primed for growth. The company anticipates that the demand for its generic medications, narcotics and controlled drugs, and branded products will fueled by, among other things, the aging Baby Boomer population. Lannett’s strong track record of regulatory compliance and manufacturing excellence, combined with strong management team, position the company well for the future.

Lannett Investor Relations
nyse openning bell

Current Stock Price $ 17.40 +0.05

Letter to Shareholders

Arthur P. Bedrosian, President and Chief Executive Officer, discusses Fiscal 2014 results.
Read, Print or Download the letter.

Annual Reports

2014       2013       2012       2011       2010       2009       2008       2007       2006

SEC Filings

Lannett Company, Inc. official SEC Filings

Section 16 Filings

Download XBRL Filings

Download Fiscal Year 2015 Q2 XBRL Filing
Download Fiscal Year 2015 Q1 XBRL Filing
Older Filings

Corporate Leadership:

Senior Management
Board of Directors

Corporate Governance:

Code of Business Conduct and Ethics
Lannett Corporate Governance Guidelines
Audit Committee Charter
Compensation Committee Charter
Governance and Nominating Committee Charter
Strategic Planning Committee Charter

Recent Webcasts


3/19/15 11:30 a.m. Pacific Time- 27th Annual ROTH Conference

02/24/15 - Lannett To Present At The RBC Capital Market 2015 Healthcare Conference February 24.

01/26/15 - Lannett Announces Preliminary Fiscal 2015 Second Quarter Net Sales Of Approximately $115 Million, EPS Between $1.18 And $1.21.

01/05/15 - Lannett To Present At The 33rd Annual J.P. Morgan Healthcare Conference On January 14.

12/09/14 - Lannett to Present at the Oppenheimer 25th Annual Healthcare Conference on December 10

11/03/14 - Lannett Reports Net Sales of $93 Million, EPS of $0.94 For Fiscal 2015 First Quarter

    More Webcasts.

Lannett Company Products